IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ:IDYA) announced that results from their Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025 in Berlin. The study includes data from over 90 patients across plaque brachytherapy and enucleation-eligible cohorts.
The presentation will highlight darovasertib's potential impact on disease management, particularly notable as it has received FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation. The company has also initiated OptimUM-10, a global Phase 3 neoadjuvant registrational trial, in Q3 2025.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA gained 5.08%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.7% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $108M to the company's valuation, bringing the market cap to $2.24B at that time.
Data tracked by StockTitan Argus on the day of publication.
- The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts
- Darovasertib has received
U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation - Initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025
"We are excited to share clinical data at ESMO 2025 on the effects of neoadjuvant darovasertib in primary uveal melanoma across both plaque brachytherapy and enucleation cohorts. Its potential to impact the natural history of this disease and its management will be highlighted in the presentation. We continue to advance our clinical strategy for darovasertib in earlier stage disease, with the recent initiation of a randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma," said Dr. Darrin Beaupre, Chief Medical Officer, IDEAYA Biosciences.
Details of the Proffered Paper Oral Presentation are as follows:
Title (Abstract #5053): Enucleation prevention and vision preservation in primary uveal melanoma (UM): preliminary results from a phase 2 study of neoadjuvant darovasertib
Presenter: Dr. Marcus
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of darovasertib, and (ii) the timing and content of a presentation on the preliminary results from a Phase 2 study of neoadjuvant darovasertib in primary UM. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2025-for-phase-2-clinical-trial-of-neoadjuvant-darovasertib-in-primary-uveal-melanoma-302513177.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the significance of IDYA's darovasertib presentation at ESMO 2025?
What regulatory designation has IDYA's darovasertib received from the FDA?
When will IDYA present the darovasertib Phase 2 results?
What is the current development stage of IDYA's darovasertib?
Who will present IDYA's darovasertib data at ESMO 2025?
